An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, United Kingdom. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4 BX, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
Pancreatic ductal adenocarcinoma continues to have a poor prognosis, although recent advances in neoadjuvant treatments (NATs) have provided some hope. Imaging assessment of suspected tumours can be challenging and requires a specific approach, with pancreas protocol CT being the primary imaging modality for staging with other modalities used as problem-solving tools to facilitate appropriate management. Imaging assessment post NAT can be particularly difficult due to a current lack of robust radiological criteria to predict response and differentiate treatment induced fibrosis/inflammation from residual tumour. This review aims to provide an update of pancreatic ductal adenocarcinoma with particular focus on three points: tumour staging pre- and post-NAT including vascular assessment, structured reporting with introduction of the PAncreatic Cancer reporting Template-UK (PACT-UK) radiology template, and the potential future role of artificial intelligence in the diagnosis and staging of pancreatic cancer.Citation
Corallo C, Al-Adhami AS, Jamieson N, Valle J, Radhakrishna G, Moir J, et al. An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. The British journal of radiology. 2025 Jan 1;98(1165):13-26. PubMed PMID: 39460945. Pubmed Central PMCID: PMC11652714. Epub 2024/10/26. eng.Journal
The British Journal of RadiologyDOI
10.1093/bjr/tqae217PubMed ID
39460945Additional Links
https://dx.doi.org/10.1093/bjr/tqae217Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/bjr/tqae217
Scopus Count
Collections
Related articles
- Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
- Authors: Panda A, Garg I, Truty MJ, Kline TL, Johnson MP, Ehman EC, Suman G, Anaam DA, Kemp BJ, Johnson GB, Halfdanarson TR, Venkatesh SK, Fidler JL, Goenka AH
- Issue date: 2021 Sep
- CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy.
- Authors: Ciaravino V, Cardobi N, DE Robertis R, Capelli P, Melisi D, Simionato F, Marchegiani G, Salvia R, D'Onofrio M
- Issue date: 2018 Aug
- Multimodality Imaging for the Staging of Pancreatic Cancer.
- Authors: McKinney M, Griffin MO, Tolat PP
- Issue date: 2021 Oct
- A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
- Authors: Guo SW, Shen J, Gao JH, Shi XH, Gao SZ, Wang H, Li B, Yuan WL, Lin L, Jin G
- Issue date: 2020 Dec
- MRI evaluation of pancreatic ductal adenocarcinoma: diagnosis, mimics, and staging.
- Authors: Bowman AW, Bolan CW
- Issue date: 2019 Mar